Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): a randomised controlled trial by Schlapbach, Luregn J et al.








Study protocol: NITric oxide during cardiopulmonary bypass to improve
Recovery in Infants with Congenital heart defects (NITRIC trial): a
randomised controlled trial
Schlapbach, Luregn J ; Horton, Stephen Brian ; Long, Debbie Amanda ; Beca, John ; Erickson, Simon ;
Festa, Marino ; d’Udekem, Yves ; Alphonso, Nelson ; Winlaw, David ; Johnson, Kerry ; Delzoppo,
Carmel ; van Loon, Kim ; Gannon, B ; Fooken, Jonas ; Blumenthal, Antje ; Young, Paul ; Jones, Mark ;
Butt, Warwick ; Schibler, Andreas ; NITRIC Study Group, the Australian and New Zealand Intensive
Car
Abstract: INTRODUCTION Congenital heart disease (CHD) is a major cause of infant mortality. Many
infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass
(CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syn-
drome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits
can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and
improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD)
(the number of days patients spend alive and free from invasive mechanical ventilation up until day 28)
compared with standard care. Here, we describe the NITRIC trial protocol. METHODS AND ANAL-
YSIS The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority
trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty
infants <2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm
administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio
with stratification by age (<6 and ฀6 weeks), single ventricle physiology (Y/N) and study centre. The
primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for
extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care
and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Pre-
planned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery.
ETHICS AND DISSEMINATION The study has ethical approval (HREC/17/QRCH/43, dated 26 April
2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and
commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a
peer-reviewed journal. TRIAL REGISTRATION NUMBER ACTRN12617000821392.
DOI: https://doi.org/10.1136/bmjopen-2018-026664






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Schlapbach, Luregn J; Horton, Stephen Brian; Long, Debbie Amanda; Beca, John; Erickson, Simon;
Festa, Marino; d’Udekem, Yves; Alphonso, Nelson; Winlaw, David; Johnson, Kerry; Delzoppo, Carmel;
van Loon, Kim; Gannon, B; Fooken, Jonas; Blumenthal, Antje; Young, Paul; Jones, Mark; Butt, Warwick;
Schibler, Andreas; NITRIC Study Group, the Australian and New Zealand Intensive Car (2019). Study
protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital
heart defects (NITRIC trial): a randomised controlled trial. BMJ Open, 9(8):e026664.
DOI: https://doi.org/10.1136/bmjopen-2018-026664
2
1Schlapbach LJ, et al. BMJ Open 2019;9:e026664. doi:10.1136/bmjopen-2018-026664
Open access 
Study protocol: NITric oxide during 
cardiopulmonary bypass to improve 
Recovery in Infants with Congenital 
heart defects (NITRIC trial): a 
randomised controlled trial
Luregn J Schlapbach,  1,2 Stephen Brian Horton,  3,4,5 Debbie Amanda Long,1,2 
John Beca,6 Simon Erickson,7 Marino Festa,8,9 Yves d’Udekem,10,11,12,13 
Nelson Alphonso,14 David Winlaw,15,16 Kerry Johnson,1,2 Carmel Delzoppo,5,17 
Kim van Loon,18 B Gannon,19 Jonas Fooken,19 Antje Blumenthal,20 Paul Young,21 
Mark Jones,22 Warwick Butt,5,17 Andreas Schibler,1,2 On behalf of the NITRIC Study 
Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group 
(ANZICS CTG), the Paediatric Critical Care Research group (PCCRG) and the 
ANZICS Paediatric Study Group (PSG)
To cite: Schlapbach LJ, 
Horton SB, Long DA, et al.  Study 
protocol: NITric oxide during 
cardiopulmonary bypass to 
improve Recovery in Infants 
with Congenital heart defects 
(NITRIC trial): a randomised 
controlled trial. BMJ Open 
2019;9:e026664. doi:10.1136/
bmjopen-2018-026664
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026664).
Received 19 November 2018
Revised 15 May 2019
Accepted 20 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Andreas Schibler;  
 a. schibler@ uq. edu. au
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Congenital heart disease (CHD) is a 
major cause of infant mortality. Many infants with CHD 
require corrective surgery with most operations requiring 
cardiopulmonary bypass (CPB). CPB triggers a systemic 
inflammatory response which is associated with low 
cardiac output syndrome (LCOS), postoperative morbidity 
and mortality. Delivery of nitric oxide (NO) into CPB circuits 
can provide myocardial protection and reduce bypass-
induced inflammation, leading to less LCOS and improved 
recovery. We hypothesised that using NO during CPB 
increases ventilator-free days (VFD) (the number of days 
patients spend alive and free from invasive mechanical 
ventilation up until day 28) compared with standard care. 
Here, we describe the NITRIC trial protocol.
Methods and analysis The NITRIC trial is a randomised, 
double-blind, controlled, parallel-group, two-sided 
superiority trial to be conducted in six paediatric cardiac 
surgical centres. One thousand three-hundred and twenty 
infants <2 years of age undergoing cardiac surgery 
with CPB will be randomly assigned to NO at 20 ppm 
administered into the CPB oxygenator for the duration 
of CPB or standard care (no NO) in a 1:1 ratio with 
stratification by age (<6 and ≥6 weeks), single ventricle 
physiology (Y/N) and study centre. The primary outcome 
will be VFD to day 28. Secondary outcomes include a 
composite of LCOS, need for extracorporeal membrane 
oxygenation or death within 28 days of surgery; length 
of stay in intensive care and in hospital; and, healthcare 
costs. Analyses will be conducted on an intention-to-treat 
basis. Preplanned secondary analyses will investigate the 
impact of NO on host inflammatory profiles postsurgery.
Ethics and dissemination The study has ethical approval 
(HREC/17/QRCH/43, dated 26 April 2017), is registered 
in the Australian New Zealand Clinical Trials Registry 
(ACTRN12617000821392) and commenced recruitment in 
July 2017. The primary manuscript will be submitted for 
publication in a peer-reviewed journal.
trial registration number ACTRN12617000821392 
IntroduCtIon
Congenital heart disease (CHD) is the most 
common congenital condition, affecting 
around one in a hundred live born children.1 
Up to 50% need cardiac surgery to correct 
the underlying abnormality at some stage 
during their life, with the majority of proce-
dures requiring cardiopulmonary bypass 
(CPB). Substantial reductions in perioperative 
mortality in children following cardiac surgery 
have been achieved,2 and adult survivors of 
CHD now outnumber paediatric patients 
strengths and limitations of this study
 ► This study tests the efficacy and safety of a simple 
intervention during cardiopulmonary bypass to im-
prove early postoperative morbidity.
 ► The intervention aims to reduce patient-centred 
adverse outcomes after a common high-risk pro-
cedure for the most common congenital condition.
 ► The study includes follow-up of neurodevelopmental 
outcome and quality of life which will allow assess-
ment of the long-term impact of the intervention.
 ► The study includes biobanking to investigate the bi-
ological mechanisms underlying the clinical findings 
in anxillary studies.
 ► The study will be the largest randomised controlled 
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with CHD in most high-income countries.3 4 Despite these 
advances, major postoperative morbidity remains common 
and is associated with increased rate of long-term mortality, 
morbidity and disability.5 The exposure of host blood to 
large artificial organ surfaces combined with myocardial 
injury during surgery, results in a strong systemic inflam-
matory response of the host, which is further aggravated 
by reperfusion injury and the release of damage-associated 
molecular patterns during surgery.6 Endotoxin release, 
leucocyte and complement activation, widespread acti-
vation of inflammatory mediators and endothelial leak7 
postoperatively contribute to low cardiac output syndrome 
(LCOS).8 9 Postoperative LCOS is clinically defined by a 
need for inotropes to maintain end organ perfusion, an 
increased arterial–venous oxygen extraction, lactataemia 
and oliguria. LCOS may lead to multiorgan failure and 
a need for extracorporeal life support (ECLS).10 Several 
studies have shown that the presence and severity of LCOS, 
which affects 25%–40% of children post-CPB in the first 
hours following heart surgery,11 is strongly associated 
with postoperative morbidity and mortality. CPB-related 
side effects are most pronounced in infants and young 
children12 due to their higher metabolic requirement, 
altered inflammatory response and higher CPB circuit to 
patient blood volume. At the same time, this age group is 
exposed to CPB during a vulnerable phase of brain devel-
opment13–15 and remains at highest risk of suffering neuro-
logical impairments16 due to acute brain injury occurring 
within the context of LCOS. Recent trials to reduce LCOS 
during cardiac surgery for CHD testing interventions such 
as steroids17 have not demonstrated consistent benefit.18 
Given the adverse effects of CPB on early recovery and long-
term neurodevelopment, there remains an urgent need for 
clinical trials evaluating novel therapies to address these 
problems.5 
Nitric oxide (NO) is an endogenous anti-inflammatory 
mediator19 and is essential to regulate endothelial func-
tion and microvascular inflammation.20 Several studies 
have demonstrated that exogenous NO can reduce 
myocardial damage in clinical and experimental settings 
of ischaemia and reperfusion.21–24 A previous small 
single-centre study in 16 children reported a reduction in 
bypass-induced inflammation using gaseous NO delivered 
at 20 ppm to CPB circuits.25 The duration of mechanical 
ventilation was significantly shorter (8.4 vs 16.3 hours; 
p<0.05) and so was intensive care unit (ICU) length of 
stay (53.8 vs 79.4 hours; p<0.05) in children receiving NO 
compared with the placebo group. We have previously 
reported the feasibility and safety of NO delivery to CPB 
in a single-centre randomised controlled pilot study in 
198 infants and children (0–16 years) undergoing cardiac 
surgery.26 This pilot study demonstrated a statistically 
significantly lower proportion of children with LCOS in 
the intervention arm, a reduced requirement for ECLS 
and a trend to reduced length of stay, and shorter dura-
tion of mechanical ventilation. The effect was greatest in 
children under 2 years of age, with the greatest treatment 
benefit observed in children under 6 weeks.
Accordingly, we designed the NITRIC trial to test the 
primary hypothesis that, in infants under 2 years having 
cardiac surgery, using NO during CPB increases ventila-
tor-free days (VFD) (the number of days patients spend 
alive and free from invasive mechanical ventilation up 
until postoperative day 28) compared with standard care. 
Here, we describe the NITRIC trial protocol.
MEthods
The NITRIC trial is a 1320 patient multicentre, 
randomised, double-blind, standard care-controlled, 
parallel-group, trial in infants and children <2 years of 
age undergoing open heart surgery on CPB (figure 1).
study setting
Tertiary/quaternary paediatric cardiac surgical services 
in Australia and New Zealand, including Cardiac and 
Paediatric Intensive Care Services of Royal Children’s 
Hospital, Melbourne; Starship Children’s Hospital Auck-
land NZ; The Children’s Hospital at Westmead, Sydney; 
Princess Margaret Hospital for Children, Perth; and 
Queensland Children’s Hospital, Brisbane and Utrecht 
Medical Center, Utrecht, The Netherlands.
Participants
Eligible children will be identified in the preoperative 
clinics, in the general cardiac wards or in the neonatal 
or paediatric intensive care unit (PICU). Included will be 
infants and children <2 years of age undergoing elective 
open heart surgery on CPB where consent of parents/
guardian is obtained prior to surgery. The exclusion criteria 
relate to patient characteristics that will interfere with 
consent, with the intervention or with measurement 
of the primary and secondary outcomes. Inclusion and 
exclusion criteria are shown in table 1.
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Enrolment of patients undergoing repeated surgery during the first 
2 years of life
In order to assess the impact of the intervention on long-
term outcomes, patients who were previously enrolled 
and randomised into the study who require a second or 
subsequent surgical procedure (such as a patient with 
single ventricle physiology requiring a staged palliation) 
will undergo the same treatment allocation for subse-
quent surgeries requiring CPB, unless parents opt out. 
Patients who were not recruited into the study during 
their first procedure, but are scheduled for a subsequent 
procedure requiring CPB prior to their second birthday, 
will be eligible for recruitment.
randomisation and blinding
Treatment assignment will be performed using a secure, 
centralised, web-based randomisation interface (Research 
Electronic Data Capture (REDCap),27 The University 
of Queensland). The allocation sequence will be gener-
ated by the study statistician using computer-generated 
random numbers using a variable block size stratified 
by age (<6 weeks, 6 weeks to 24 months), univentricular 
versus biventricular lesions, and by site. Of the inves-
tigating team, only the study perfusionist will be aware 
of the randomisation and NO delivery. Cardiologists, 
cardiac surgeons, anesthesiologists, intensivists, PICU 
nurses, research assistants, data analysts, and parents and 
caregivers will be blinded for the intervention. Rationale 
for stratification: the age group under 6 weeks represents 
the cohort at highest surgical risk. In the pilot study, 
the effect size of the NO delivery was greatest in these 
infants.26 Cardiac physiology (univentricular vs biventric-
ular) is a major determinant of surgical complexity, risk 
and outcome.1 5
blinding of the intervention
Blinding arrangements in the operating theatre will 
be achieved by covering the NO delivery system with 
drapes. The dedicated study NO delivery system will be 
connected to the CPB oxygenator at all times, indepen-
dent of randomisation. The family, surgeons, anaesthe-
tists and PICU staff will be not aware of the treatment arm 
a patient is allocated to. The perfusionists will be advised 
that all aspects of CPB except for provision of NO (or 
not) should be performed according to standard institu-
tional practice for study participants.
Interventions
Infants will be randomly assigned to NO or standard care. 
Those allocated to the NO arm will receive NO during CPB 
Table 1 Inclusion and exclusion criteria
Patient group Criterium Definition
Inclusion Age  ► Postnatal age <2 years.
Procedure  ► Open elective heart surgery.
 ► Cardiopulmonary bypass used during surgery.
Consent  ► Parental/caregiver consent available prior to surgery.
Exclusion Age  ► Age ≥2 years.
Procedure  ► Emergency cardiac surgery which may preclude obtaining informed consent (acutely 
required life-saving procedure in a patient unlikely to survive the next hours without 
the surgery).
 ► Heart surgery not requiring cardiopulmonary bypass.
Consent  ► Lack of parental/caregiver consent.
Pulmonary hypertension  ► Persistently elevated pulmonary vascular resistance preoperatively receiving inhaled 
NO or preoperative intravenous use of drugs involved in the NO pathway such as 
glyceryl trinitrate within 48 hours prior to CPB (oral sildenafil treatment alone is not 
an exclusion).
Preoperative disease  ► ECLS immediately prior to surgery.
 ► Receiving ongoing treatment with antimicrobials for confirmed or suspected sepsis 
or septic shock diagnosed within 48 hours prior to the time of surgery.
 ► Treated with high doses of vasoactive drugs defined as a Vasoactive-Inotrope 
Score ≥15 within 24 hours prior to surgery.*
 ► Cardiac arrest within 1 week (7 days) prior to surgery.
 ► Acute respiratory distress syndrome requiring high-frequency oscillatory ventilation 
within 48 hours prior to surgery.
 ► Chronic ventilator dependency (patients treated with non-invasive or invasive 
ventilation continuously for >28 days prior to cardiopulmonary bypass).
 ► Pre-existing methaemoglobinemia (>3%).
*Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary 
bypass. Pediatr Crit Care Med 2010;11:234–8.
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blended into the fresh gas flow of the CPB oxygenator, 
which is kept at 3 L/min. NO levels are maintained at 20 
ppm using a NO delivery system (Ikaria INOmax DSIR, 
Ikaria, NJ, USA) or similar device. Continuous sampling 
of NO and NO
2
 concentration will be undertaken from 
an access port before the oxygenator. NO will be started 
immediately when the patient is placed on CPB and ceased 
once weaned off CPB. Patients allocated to the standard 
study arm will receive the standard gase oxygen–air mix into 
the CPB oxygenator at a flow rate of 3 L/min. If patients 
require several CPB runs during the same procedure, the 
study treatment will be provided for each CPB run using 
the same treatment allocation for every CPB run.
relevant concomitant perioperative care
Arterial partial pressures of CO
2
 will be maintained 
constantly in both study arms as per institutional prac-
tice (following each centre’s protocols on alpha/pH stat 
and temperatures). The FiO
2
 of the fresh gas flow will be 
set between 21% and 100%, according to centre-specific 
CPB protocols. Techniques of anaesthesia and surgery 
will not be specified to allow site-specific individual prac-
tice. The decision whether a patient requires treatment 
with inhaled NO (iNO) into the ventilator circuit prior 
to, during or after CPB remains at the discretion of the 
treating physicians (anaesthetists, cardiac surgeons or 
intensivists) independent of treatment allocation. The 
postoperative care and decisions on inotropes and other 
vasoactive drug delivery, fluid management, renal replace-
ment therapy, iNO therapy or indication for ECLS will be 
performed as per site-specific standard protocols of care.
study outcomes
The primary outcome is VFD for the first 28 days postran-
domisation (table 2). The primary outcome will be 
measured using duration of invasive respiratory support 
for all episodes with an endotracheal tube in situ for the 
first 28 days postrandomisation. A systematic zero value 
will be assigned for patients who die to weigh death as 
the most pejorative outcome. Treatment with non-in-
vasive ventilation and high-flow nasal cannulae will not 
be considered as ventilator days. Secondary outcomes are 
defined as the composite outcome compromising LCOS, 
need for postoperative ECLS or 28-day mortality; ICU and 
hospital length of stay; and healthcare costs. In addition, 
the long-term outcome of patients will be followed up at 
12 months postprocedure.
Low cardiac output syndrome
LCOS10 is defined as a blood lactate level >4 mmol/L 





gradient >35%) within the first 48 hours postoperatively, 
or a high inotrope requirement defined as Vasoactive-Ino-
trope Score ≥15.28 29
Rationale for primary and secondary outcomes
VFD represents one of the strongest predictors of short-
term and long-term outcomes,10 including length of 
ICU stay, morbidity (impaired neurodevelopment, 
hospital-acquired infections) and mortality. VFD directly 
reflect intensive care resource use and healthcare costs.30 
VFD fulfils Specific, Measurable, Achievable, Realistic 
and  Timely criteria. LCOS is directly related to VFD, as 
infants usually do not tolerate weaning or fail extuba-
tion if LCOS and organ dysfunction have not resolved. 
The composite of LCOS, ECLS use and mortality as a 
secondary end point, is a strong patient-centred outcome 
and directly relates to the intervention in terms of biolog-
ical plausibility.
Adverse events
It is recognised that the postoperative paediatric cardiac 
surgical patient population will experience a number of 
common aberrations in laboratory values, signs and symp-
toms due to the severity of the underlying disease and the 
impact of standard therapies. Intensive care patients will 
frequently develop life-threatening organ failure(s) unre-
lated to study interventions and despite optimal manage-
ment. Therefore, consistent with established practice in 
academic ICU trials,31 events that are part of the natural 
history of the primary disease process or expected compli-
cations of critical illness will not be reported as serious 
adverse events in this study. All adverse events which are 
considered to be potentially causally related to the study 
intervention or are otherwise of concern in the investiga-
tor’s judgement will be reported unless they are prespeci-
fied study outcomes. Specific adverse events related to NO 
delivery during CBP include air embolism, severe hypoten-
sion during bypass and increased methaemoglobinemia 
(>3%). Of note, in previous studies, methaemoglobin values 
using NO at 20 ppm were similar in both the control and 
intervention groups (1.4%).25 26 Events that are collected as 
study outcomes will not be reported as adverse events.
safety data monitoring
The Data Safety Monitoring Board (DSMB) consists of 
a general and a cardiac paediatric intensivist, a cardiac 
surgeon and a statistician. None of the DSMB members 
will be involved in recruitment of study patients at their 
site. DSMB members will not be supervised by any study 
investigator or participate as investigators in any study 
currently under review by this DSMB. The primary objec-
tive of the DSMB is to monitor the safety of the interven-
tion and the validity and integrity of the data from the 
NITRIC study. Additionally, the DSMB will evaluate the 
pace of recruitment and will make recommendations 
to the NITRIC Chief investigator(s) and Steering Board 
regarding the continuation, modification or termina-
tion of the study. The DSMB will evaluate on an ongoing 
basis, the accumulating safety assessments to ensure the 
ongoing safety of study subjects. The DSMB will meet via 
teleconference call after recruitment of 660, and of 1000 
children, respectively, and on trial completion.
The DSMB can request unblinding in the event of a 
serious adverse event defined as a cardiac arrest, need 
for ECLS, or other incident leading to permanent harm 
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sample size
A pilot study of 134 patients aged <2 years showed a 
2.74 days (66 hours) increase in VFD associated with the 
study intervention.26 This includes patients who died, 
who were considered as zero VFDs. The VFD increase 
associated with the intervention represents an effect size 
of 0.33 SD based on a SD of 8.1 days in the pilot study 
control group. Based on the primary outcome measure 
VFD, 1320 patients (660 per group) will be required to 
demonstrate a significant increase in VFD assuming a 
minimally clinically significant effect size (0.2 SD; 1.66 
days or 40 hours), 90% power, two-sided alpha level of 
significance of 5%, 10% withdrawals and 15% increase in 
sample size to account for a non-normal distribution of 
VFD. In Australia and New Zealand, ~800 of children <2 
years of age undergo surgery for a congenital heart defect 
requiring CPB each year, including patients with multiple 
procedures. The consent rate of eligible patients was 78% 
in the pilot trial.26 With an expected conservative esti-
mate 60% enrolment rate of eligible patients, we expect a 
3.5-year recruitment period for the study.
data collection, management and analysis
Data collection
Baseline variables (demographics, primary cardiac diagnosis, 
comorbidities including syndromes), preoperative disease 
Table 2 Study outcomess
Outcome Criterium Definition
Primary Ventilator-free days  ► Duration of respiratory support for all episodes for the first 28 days 
postrandomisation.
 ► Zero value for patients dying within 28 days postrandomisation.
 ►  Refers to invasive respiratory support with an endotracheal tube in situ. 
 ►  Treatment with non-invasive ventilation and high-flow nasal cannulae will not 
be considered as ventilator days. 
Secondary Composite outcome of low 
cardiac output syndrome 
(LCOS), extracorporeal life 
support (ECLS) or death
 ► LCOS is defined as one or more of the following*:





gradient >35%) within the first 48 hours postoperatively.
 – A high inotrope requirement defined as Vasoactive-Inotrope Score ≥15 
(VIS)† where VIS=dopamine dose (μg/kg/min)+dobutamine dose (μg/kg/
min)+100 x epinephrine dose (μg/kg/min)+100 x norepinephrine dose (μg/
kg/min)+10 x milrinone dose (μg/kg/min)+10 000 x vasopressin dose (U/kg/
min).
 ► ECLS is defined as treatment with ECLS during the first 48 hours 
postrandomisation.
 ► Death is defined as death occurring within the first 28 days postrandomisation.
Length of stay  ► Length of stay in paediatric intensive care unit (PICU).
 ► Length of stay in hospital. 
Costs  ► Healthcare related costs.
Neurodevelopmental and 
functional outcome at 12 months
 ► Ages and Stages Questionnaire scores below threshold for at least one of the 
five domains measured 12 months postrandomisation and quality of life.
Process of care 
measures
Severity indicators  ► Treatment with ECLS postoperatively.
 ► Duration of postoperative time spent with open chest including unplanned 
chest reopening.
 ► Treatment and duration of treatment using inhalational nitric oxide 
postoperatively. 




Host inflammation  ► Serum cytokine levels measured during the first 24 hours.
 ► Inflammation markers measured during the first 24 hours.
Myocardial injury  ► Levels of postoperative serum troponin levels measured during the first 
24 hours.
Organ dysfunction  ► Severity and duration of postoperative organ dysfunction measured by 
PELOD-2.
 ► Postoperative acute kidney injury and serum creatinine levels measured during 
the first 24 hours. 
 ► Severity and duration of postoperative delirium.  
*Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and 
children after corrective surgery for congenital heart disease. Circulation 2003;107:996–1002.
†Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after 
cardiopulmonary bypass. Pediatr Crit Care Med 2010;11:234–8.





















































































































6 Schlapbach LJ, et al. BMJ Open 2019;9:e026664. doi:10.1136/bmjopen-2018-026664
Open access 
severity, surgical data (length of CPB and cross-clamp, type 
of surgery and complexity score, other CPB characteristics, 
blood product usage), primary end points, secondary end 
points, predetermined physiological variables of interest 
and process of care measures will be prospectively recorded 
into a study REDCap online database. Plausibility and range 
checks are implemented. Paired arterial and venous gases 
will be collected postoperatively at 0, 6, 12, 24 and 48 hours 
(in PICU until discharge to the ward or removal of arterial 
and central venous lines, whichever occurs first) to assess 




 gradient. Key physiological and 
blood parameters and Paediatric Logistic Organ Dysfunc-
tion-2 scores32 will be measured at 0, 6, 12, 24 and 48 hours 
postadmission or until PICU discharge whichever occurs 
earlier. Delayed chest closure, use of iNO and duration of 
circulatory, renal and ventilatory support postoperatively 
will be recorded. Gross functional performance assessment 
will be recorded on admission to PICU and on discharge 
from hospital.33 Neurological and functional outcome 
(including phone interviews with parents/caregivers) will 
be assessed at 12 months postoperatively using Ages and 
Stages Questionnaires34 35 and assessment of quality of life 
using paediatric quality of life inventory.36 Details on the 
long-term follow-up will be published separately.
Biobanking
Blood markers for myocardial injury and inflammatory 
response will be collected on induction of anaesthesia 
(baseline—prebypass), at admission to PICU (0 hours—
postbypass) and at 12, and 24 hours, in patients where 
parents consent to biobanking. Blood will be collected 
presurgery as preoperative baseline (before onset of 
cardiac surgery, done by the anaesthetist during the 
induction of the patient once the arterial line has been 
inserted): 1–2 mL of EDTA blood (for DNA), 2.5 mL of 
PAXgene blood (for gene expression markers), 1–2 mL of 
serum; and postoperatively at 0, 12 and 24 hours (in PICU 
until discharge to the ward): 2.5 mL of PAXgene blood 
(time point 0), and 1–2 mL of serum. The samples will 
be processed, stored and shipped according to accepted 
international standards and batch analysed.
The investigators are responsible for ensuring the accu-
racy, completeness, legibility and timeliness of the data 
reported. The investigators will maintain adequate case 
histories of study participants, including accurate case 
report forms (CRFs), and source documentation. Data 
will be prospectively entered into a secure web-based 
database (REDCap; https:// redcap. health. uq. edu. au/), 
hosted by the University of Queensland. Printed paper 
CRFs will be available if required. All study information 
and documentation will be securely stored for a period of 
15 years after the date of the child’s 18th birthday.
statistical analysis plan
Analysis plan
Analyses will apply the intention-to-treat principle. 
Descriptive statistics will be used to describe baseline 
characteristics of the study cohort and each subgroup 
by treatment group. The primary outcome measure 
will be analysed using a Mann-Whitney U test as VFD is 
non-normally distributed variable. Analysis of secondary 
outcomes includes both comparisons of measurements 
and proportions, using CIs of differences as the major 
method of presentation where possible, otherwise stan-
dard techniques such as Mann-Whitney U tests, t-tests 
and χ2 tests will be utilised. Survival outcomes will be 
compared between treatment groups using Kaplan-Meier 
product limit method and log-rank test. Statistical signifi-
cance will be set at the 0.05 level for the primary outcome.
A safety and efficacy interim analysis after 660 (the 
half-way point), and after 1000 enrolled patients will be 
performed by an independent statistician to evaluate for 
safety endpoints, to assess the predictive probability of 
reaching the study goals and compare VFD between treat-
ment groups. Consideration to stopping the trial early by 
an independent DSMB will be based on safety concerns, 
futility or strong evidence of a difference between groups 
for VFD (based on a Haybittle-Peto boundary p=0.001). 
A detailed analysis plan specifying statistical analyses 
including health economic analyses will be placed in the 
public domain prior to recruitment of the last participant.37
Biomarker measurements
Nested substudies will be performed in selected samples 
at sites performing biobanking (1) to test the impact 
of the intervention on markers of systemic and myocar-
dial inflammation, (2) to compare treatment response 
between patients depending on preintervention 
severity assessed by markers of inflammation and organ 
failure and (3) to biochemically define responders to 
the intervention (to identify patient subgroups preran-
domisation that are more likely to respond to a specific 
treatment). The use of samples/data will be governed by 
the study steering board and resulting publications must 
appropriately acknowledge the study. Combining a large 
RCT with a nested biobank is recommended to maximise 
scientific knowledge.38
Health economic evaluation
A within trial economic evaluation will be used to deter-
mine if providing NO is cost-saving compared with usual 
care from the health system perspective. A comprehensive 
cost-effectiveness analysis will be undertaken to determine 
the level of cost savings (if any). Length of stay (in PICU and 
in non-intensive stay) will be the main outcome variable. 
Resources used before first discharge will be compared 
between treatments. Resources will subsequently be costed, 
based on hospital cost centre or standard national sources 
(eg, Independent Hospital Pricing Authority).
Monitoring
The study leadership team is responsible for 100% moni-
toring of investigator and study nurse credentials, training 
records and delegation of responsibility logs, and will 
review 100% of consent forms. CRFs will be compared 
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and complete. One hundred per cent of source data veri-
fication of eligibility criteria and the primary outcome 
and the composite secondary outcome of LCOS, ECLS 
or death will be performed. An independent monitoring 
per each site will monitor the data fields required for 
eligibility, primary and secondary study endpoints, and 
serious adverse events (SAEs) using primary source veri-
fication. In addition, site visits and regular monitoring of 
the blood sample storage will be performed.
Patient and public involvement
Consumers and the public were consulted to design a 
video informing parents about the study. Patients and the 
public had no other involvement in study design.
Ethics
This protocol and the informed consent document and 
any subsequent modifications have been reviewed. This 
study will be conducted in compliance with the current 
version of the protocol. Any change to the protocol docu-
ment or informed consent form that affects the scientific 
intent, study design, patient safety, or may affect a partic-
ipants’ willingness to continue in the study is considered 
an amendment, and therefore will be written and filed as 
an amendment to this protocol and/or informed consent 
form. All protocol deviations must be recorded in the 
patient record (source document) and on the CRF and 
must be reported to the principal investigator (PI). Protocol 
deviations will be assessed for significance by the PI.
Consent will be sought from the parents of every 
child <2 years of age undergoing CPB for elective cardiac 
surgery over the study period. When the family is seen by 
the surgeons in preassessment clinic (usually days prior 
to surgery), the study will be mentioned to them by the 
surgeon. In addition, the study team will provide study 
information prior to hospitalisation to families, including 
printed study flyers, and links to online study documenta-
tion (media release). Participant confidentiality is strictly 
held in trust by the participating investigators, research 
staff and the sponsoring institution and their agents. The 
study protocol, documentation, data and all other infor-
mation generated will be held in strict confidence.
Significance
Postoperative paediatric cardiac surgical patients have a 
high consumption of intensive care resources and remain 
at very high risk of major complications, including cardiac 
arrest, death and long-term neurological impairment. 
Approximately 10% of children with CHD survive with 
major neurological sequelae postoperatively, resulting in 
a massive lifelong burden for patients, families, health-
care systems and the society.13 An attempt to reduce 
LCOS and hence perioperative morbidity has the poten-
tial to translate not only to a reduction in intensive care 
resource utilisation but also to impact positively on long-
term outcomes. Side effects from heart surgery for CHD 
translate into long-term morbidity, persisting into adult 
life with a major impact on other family members and 
society. This study will deliver the high-level randomised 
evidence with the potential to show a reduction in post-
operative morbidity and mortality in children with CHD.
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